Saxenda is the brand name for liraglutide when it is prescribed for chronic weight management. It is a GLP-1 receptor agonist made by Novo Nordisk and is given as a once-daily subcutaneous injection (Saxenda prescribing information (external link)).
The same medication is sold as Victoza at lower doses for type 2 diabetes. As of September 2026 there are US generics of both: the first generic of Saxenda was approved and launched in August 2025 (Teva (external link)), and generic Victoza has been available since December 2024.